OEM Customer Loss Drives Revenue Miss on Syneron Medical Ltd (ELOS); Leerink Partners Cuts Price Target to $9.40
Leerink Partners maintained an Outperform rating on Syneron Medical (NASDAQ: ELOS), and cut the price target to $9.40 (from $16.00) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)